DISCLAIMER: This article is for informational and educational purposes only. All products referenced are sold strictly for laboratory and research use by qualified professionals. Not for human consumption, veterinary use, or diagnostic use.
Retatrutide is another emerging peptide in metabolic research, currently in trials for body weight regulation, glucose metabolism, lipid balance, and energy expenditure.
Whereas trizep is a dual-receptor agonist that targets both GLP-1 and GIP, retratutide is a triple-receptor agonist that also targets GLP-1, GIP, and GCG (glucagon) receptors in the body, which, when proven successful, may support a broader metabolic signaling strategy than earlier incretin-based compounds.
This guide summarizes everything to know about retatrutide for research use, including its chemistry, mechanism of action, experimental applications, and current clinical findings.
What is Retatrutide and How Does It Work?
Retatrutide is a synthetic peptide classified as a triple hormone receptor agonist that targets GPL-1, GIP, and GCG receptors. It belongs to a newer category of incretin-based investigational peptides being studied for metabolic research.
It can target what single (e.g., sema) and dual-receptor (e.g., trizep) agonists do, such as slowing digestion, reducing appetite, improving blood sugar regulation, and regulating insulin secretion.
Moreover, as a triple agonist, retatrutide also targets glucagon receptors, which can potentially increase energy expenditure or calorie burning, and improve body fat mass.
Retatrutide consists of 39 amino acids in a linear chain, with specific substitutions and synthetic modifications, and was intentionally engineered to combine the actions of three distinct hormonal pathways (GLP-1, GIP, and GCG) into a single molecule.
RETATRUTIDE
Molecular Formula: C₂₀₆H₃₁₂N₄₈O₆₃S
Molecular Weight: 4483.54 g/mol
Amino Acid Sequence: His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Leu-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Phe-Leu-Leu-Gly-Lys-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser
Important Note: True Peptides’ retatrutide peptide for sale is NOT intended for human or clinical use. It is only approved for laboratory and experimental use.
Ongoing Clinical Trials on Retratutide
As of this writing, the Food and Drug Administration has not issued any approvals for medications containing retatrutide, as most clinical trials for this triple agonist receptor are still in phase 3, except for one.
TRIUMPH 4, the first successful phase 3 trial involving retatrutide published in December 2025, resulted in participants with obesity and knee osteoarthritis losing an average of 28.7% of their body weight. This, after taking retatrutide at 12 mg for 68 weeks.
Apart from weight loss, participants also reported reduced pain and significant improvement in physical function related to their knee condition, with more than 1 in 8 participants completely pain-free.
Other ongoing clinical trials also focus on retatrutide’s possible effects on weight management, body weight maintenance, cardiovascular health, and related metabolic conditions such as diabetes and non-alcoholic fatty liver disease.
The studies involve participants of different ages (18+ to 45+) with different conditions, or a combination of conditions, including obesity without diabetes (TRIUMPH-9), obesity with knee osteoarthritis and/or obstructive sleep apnea (TRIUMPH-1), type-2 diabetes with obesity and/or obstructive sleep apnea (TRIUMPH-2), obesity + cardiovascular disease (TRIUMPH-3), and obesity + chronic back pain (TRIUMPH-7).
Some of the clinical trials also compared retatrutide with other comparators: placebo for weight reduction and weight-loss maintenance (TRIUMPH-6 and -8), trizep (TRIUMPH-5), and sema for type 2 diabetes and inadequate glycemic control with metformin (TRANSCEND-T2D-2).
Another study, TRIUMPH-Outcomes, is also underway and aims to evaluate retatrutide’s possible effect on lowering heart-related complications or preventing worsening of kidney function in overweight participants.
Best Practices for Handling Retatrutide for Research Use
Correct handling, storage, and reconstitution will preserve retatrutide’s biological activity, which can directly impact an experiment’s results.
How to Store Research Retatrutide
Lyophilized retatrutide must be stored at -20ºC to -80ºC for long-term storage, or at -2ºC to -8ºC for short-term storage (under 4 weeks). The environment should be completely dry, in a desiccator or with desiccant packs, and should be away from light.
Frozen vials must be brought to room temperature before opening to prevent moisture buildup that can affect the peptide’s integrity. Freeze-thaw cycle should also be avoided, so it’s best to portion the peptides into small aliquots.
Reconstituted retatrutide, on the other hand, must always be stored in the refrigerator at 2ºC to 8ºC. Retatrutide contains amino acids that are sensitive to UV light; storing it in opaque containers or bags away from light will protect the compound from photo-oxidation.
Freezing may completely destroy the peptide’s efficacy, so the reconstituted compounds need proper, careful storage.
How to Reconstitute Research Retatrutide
Retatrutide is commonly dissolved in Bacteriostatic water. The benzyl alcohol in BAC water acts as a preservative, inhibiting microbial growth in the compound and allowing multiple withdrawals from the same vial.
However, to reach higher concentrations, as some retatrutide compounds require for research purposes, the lyophilized retatrutide is often dissolved in an organic solvent first, such as DMSO or acetonitrile, followed by dilution into aqueous buffers
RELATED: How to Optimize Peptide Solubility for Experimental Use
Working in a sterile environment with personal protective equipment is important to prevent accidents and contamination of the compound.
The basic supplies needed are the lyophilized retatrutide, solvent, syringes, disinfectant (such as alcohol wipes), and proper disposal containers.
Introduce the solvent slowly to the peptide. Aim the needle so the solvent trickles down the inside wall of the glass rather than spraying forcefully.
Do not shake the vial; gentle swirling is recommended to prevent peptide degradation. If necessary, a sonicator may be used to improve efficiency.
Learn more about the best practices when handling, storing, and reconstituting peptides in laboratories below:
- Research Peptides for Laboratory Use: Best Practices and Standards
- How to Store Peptides for Long-Term Research Use
- How to Reconstitute Peptides for Laboratory Use
Why Trust True Peptides’ Retatrutide Peptide for Sale
True Peptides is committed to meeting the high standards expected in peptide sciences and laboratory research. Our high-purity research peptides at 99%+ are supported by analytical verification from our manufacturers and third-party testers.
Every lot of our compounds is tested; not spot checked, not randomly sampled.
Customers can expect:
- Properly labeled vials with a unique lot number for easy tracking. This lot number is linked to the purity percentage, documented quantity, and a Certificate of Analysis, which clients can check on the product page before ordering.
- Full matching documentation. Each lot gets its own paperwork and testing. No recycled COAs.
- Full traceability. Every vial, COA, and test result is linked together. Customers can trace any product back to its lot, its test data, and its source documentation.
True Peptides maintains our transparency and integrity by providing high-quality research peptides that researchers can trust. We ship orders placed before 2 PM CST, and our support team is just an email away to assist with any queries.
See more of our high-purity research peptides here:
FAQs About Retatrutide for Research Use
How does retatrutide differ from trizep?
Retatrutide activates three metabolic receptors (GLP-1, GIP, and glucagon), while trizep targets two (GLP-1 and GIP only).
The added glucagon receptor activity in retatrutide is associated with increased energy expenditure in preclinical and clinical research.
Structurally, both are synthetic peptide analogs, but they differ in their receptor activity profiles and molecular designs.
Why is retatrutide supplied as a lyophilized powder?
Lyophilization (freeze-drying) improves peptide stability by removing water, which reduces degradation pathways such as hydrolysis and oxidation.
Peptides like retatrutide are more stable in dry form during shipping and long-term storage. The powder is typically reconstituted with sterile solvent prior to laboratory use.
What analytical methods are commonly used to verify retatrutide quality?
The most common methods are High-performance liquid chromatography (HPLC), used to assess purity and detect impurities, and Mass spectrometry (MS), which confirms molecular weight and structural integrity.
Additional methods such as peptide mapping, amino acid analysis, and stability testing may also be used to ensure batch consistency and quality.
DISCLAIMER: Products sold by True Peptides are intended for laboratory and research use only. They are not drugs, food, or dietary supplements, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or animal consumption.
REFERENCES+
- Pasqualotto, E., Ferreira, R., Chavez, M., Hohl, A., Ronsoni, M., Pasqualotto, T., de Moraes, F., Hespanhol, L., Watanabe, J., Lütkemeyer, C., de Sande-Lee, S. (2024) Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, Volume 24, 100321, ISSN 2589-9368. https://doi.org/10.1016/j.metop.2024.100321.
- Coskun, T., Wu, Q., Schloot, N., Haupt, A., Milicevic, Z., Khouli, C., Harris, C. (2025) Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. The Lancet Diabetes & Endocrinology, Volume 13, Issue 8, Pages 674-684, ISSN 2213-8587. https://doi.org/10.1016/S2213-8587(25)00092-0
- https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average
- CLINICAL TRIALS:
https://clinicaltrials.gov/study/NCT07357415
https://clinicaltrials.gov/study/NCT07232719
https://clinicaltrials.gov/study/NCT07035093
https://clinicaltrials.gov/study/NCT06260722
https://clinicaltrials.gov/study/NCT06662383
https://clinicaltrials.gov/study/NCT06859268
https://clinicaltrials.gov/study/NCT05929066
https://clinicaltrials.gov/study/NCT06383390